Tetratrichomonas and Trichomonas spp.-Associated Disease in Free-Ranging Common Eiders (Somateria mollissima) from Wellfleet Bay, MA and Description of ITS1 Region Genotypes

During an outbreak of Wellfleet Bay virus (WFBV) in common eiders (Somateria mollissima) from the Cape Cod region of Massachusetts, several birds were diagnosed with trichomonosis consisting of multiple trichomonad species. Six birds were examined, with trichomonads found in ceca in four birds and associated typhlitis in three of these four birds. PCR and DNA sequencing utilizing trichomonad-specific primers targeting the ITS1 region of the ribosomal DNA (rDNA) revealed the presence of Tetratrichomonas gallinarum in the gastrointestinal tracts of five birds and Trichomonas spp. in the livers of two birds, one of which had a dual Te. gallinarum-Trichomonas gallinae infection. Sequence analysis revealed no variation between Te. gallinarum sequences whereas the ITS1 sequences obtained from the other Trichomonas spp. demonstrated the presence of multiple genotypes. One sequence had 100% identity to a Trichomonas sp. previously isolated from a Cooper\u27s hawk (Accipiter cooperii) and the other sequence was 100% identical to a previously described Tr. gallinae isolate obtained from a Pacific Coast band-tailed pigeon (Patagioenas fasciata monilis). These findings suggest Te. gallinarum and other Trichomonas spp. possibly contributed to morbidity and mortality in this species. Furthermore, to the authors\u27 knowledge, this is the first report of trichomonad-associated disease in a free-ranging sea duck

Recent increase of surface particulate matter concentrations in the Seoul Metropolitan Area, Korea

Recent changes of surface particulate matter (PM) concentration in the Seoul Metropolitan Area (SMA), South Korea, are puzzling. The long-term trend of surface PM concentration in the SMA declined in the 2000s, but since 2012 its concentrations have tended to incline, which is coincident with frequent severe hazes in South Korea. This increase puts the Korean government's emission reduction efforts in jeopardy. This study reports that interannual variation of surface PM concentration in South Korea is closely linked with the interannual variations of wind speed. A 12-year (2004-2015) regional air quality simulation was conducted over East Asia (27-km) and over South Korea (9-km) to assess the impact of meteorology under constant anthropogenic emissions. Simulated PM concentrations show a strong negative correlation (i.e. R = -0.86) with regional wind speed, implying that reduced regional ventilation is likely associated with more stagnant conditions that cause severe pollutant episodes in South Korea. We conclude that the current PM concentration trend in South Korea is a combination of long-term decline by emission control efforts and short-term fluctuation of regional wind speed interannual variability. When the meteorology-driven variations are removed, PM concentrations in South Korea have declined continuously even after 2012

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)